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==========

Compared with the increased availability of molecular targeted therapies, including numerous protein kinase inhibitors (PKIs), the development of clinical tests to identify patient subgroups most likely to benefit from these therapies is lagging behind. A particular clinical need exists for tools to enable selection of multitargeted PKIs and for patients with advanced solid tumors refractory to standard treatment, who could benefit from repurposing of available drugs. Several potentially useful tumor‐profiling platforms such as peptide and (reverse phase) protein microarrays have been suggested to infer kinase activity for treatment stratification or target identification \[[1](#onco12594-bib-0001){ref-type="ref"}\], \[[2](#onco12594-bib-0002){ref-type="ref"}\], \[[3](#onco12594-bib-0003){ref-type="ref"}\], \[[4](#onco12594-bib-0004){ref-type="ref"}\], \[[5](#onco12594-bib-0005){ref-type="ref"}\], \[[6](#onco12594-bib-0006){ref-type="ref"}\]. Preclinical and clinical data have shown some indications that a 144‐tyrosine kinase peptide substrate microarray may be of value for treatment selection \[[7](#onco12594-bib-0007){ref-type="ref"}\], \[[8](#onco12594-bib-0008){ref-type="ref"}\]. Hypothesizing that microarray‐based kinase activity profiling may be a potential clinical tool for PKI treatment selection in patients refractory to standard treatment, we performed a molecular profiling study to select treatment with a registered PKI by in vitro assessment of their inhibitory effect on kinase activity profiles using lysates obtained from fresh tumor biopsy.

Adult patients with biopsy‐accessible disease of an advanced solid malignancy, for whom no standard treatment was available, were eligible. Sunitinib, dasatinib, sorafenib, erlotinib, lapatinib, and everolimus were analyzed for their inhibition of kinase activity. Extrapolation of in vitro inhibitory potency to their presumed clinical activity was based on an algorithm considering, per drug, the number of significantly inhibited peptides and percentage of inhibition. The most potent PKI in this assay was then selected for treatment.

Thirteen patients were enrolled. Kinase activity profiling was performed for 12 patients; dasatinib was selected for 9 patients, sunitinib for 2 patients, and erlotinib for 1 patient. Eight of eleven patients who subsequently initiated the selected treatment were evaluable for response. One patient with biliary tract cancer had stable disease (SD) on sunitinib for more than 4 months. One patient treated with dasatinib showed SD at 6 weeks but progressive disease (PD) at 12 weeks; the remaining patients had PD at first evaluation (Fig. [1](#onco12594-fig-0001){ref-type="fig"}). Based on our findings after 11 treated patients that dasatinib was selected in 75% of patients but resulted in clinical benefit in \<10% of patients within 6 weeks, we concluded by statistical means that the chance for the trial to succeed to stage II according to prespecified criteria was \<1%. The trial was therefore prematurely halted.

![Two of thirteen patients who gave informed consent could not start treatment; one patient progressed rapidly before completion of tumor profiling, and one patient became ineligible after profiling. Three patients for whom dasatinib was selected were not evaluable for response due to early clinical progression (*n* = 2) and patient\'s refusal of selected treatment (*n* = 1).\
Abbreviations: PD, progressive disease; PFS, progression‐free survival; PKI, protein kinase inhibitor; SD, stable disease.](onco12594-fig-0001){#onco12594-fig-0001}

In conclusion, we here show that PKI inhibition profiles can be reliably determined using needle biopsies from patients with refractory solid tumors. However, the microarray‐based selection strategy was insufficient in predicting clinical benefit upon treatment with the selected PKI. We anticipate that the concentrations used in this in vitro assay should be re‐evaluated based on achieved PKI tumor concentrations in patients.

Trial Information {#onco12594-sec-0007}
=================

**Disease**Advanced cancer/solid tumor only**Stage of Disease/Treatment**Metastatic/advanced**Prior Therapy**No designated number of regimens**Type of Study -- 1**Phase II**Type of Study -- 2**Interventional molecular profiling study**Primary Endpoint**Feasibility and clinical benefit rate (CBR), defined as the partial response (PR), complete response (CR), and SD rate after 12 weeks, of treatment selection by tumor kinase activity profiling**Secondary Endpoint**Progression‐free survival (PFS) ratio (PFS~2~/PFS~1~) of a PKI selected by kinase activity profiling (PFS2) compared with the PFS of the treatment regimen on which the patient progressed prior to study inclusion (PFS1)**Additional Details of Endpoints or Study Design** Based on the CBR of approximately 10% observed in phase I studies of the registered PKIs used in this study, we hypothesized that the microarray‐based selection would increase the CBR of PKI treatment in this patient population refractory to standard treatment from 10% to 25%. Based on Simon\'s two‐stage optimal trial design, it was calculated that 43 patients (18 in stage I and 25 in stage II) needed to be treated. The interim analysis after stage I required demonstrated clinical benefit for at least 3 of 18 patients to proceed to stage II, in which 25 more patients would be included. If at least 8 of the total 43 patients would demonstrate clinical benefit, the null hypothesis that this treatment selection strategy is only effective in 10% of patients would be rejected. If in stage I ≤2 of the 18 patients would have clinical benefit at 12 weeks of treatment, the study would be terminated due to lack of acceptable clinical benefit (efficacy) of this approach. Based on these considerations, this trial was calculated to have 80% power to detect CBR of 25% versus the null rate of 10% with a 5% Type I error rate. **Investigator\'s Analysis**Level of activity did not meet planned endpoint

Drug Information for Phase II Standard (Treatment Selection) Arm {#onco12594-sec-0008}
================================================================

Drug 1 Generic/Working NameSunitinibDose50 mg per flat doseRoutep.o.Schedule of AdministrationOnce dailyDrug 2 Generic/Working NameErlotinibDose150 mg per flat doseRoutep.o.Schedule of AdministrationOnce dailyDrug 3 Generic/Working NameSorafenibDose400 mg per flat doseRoutep.o.Schedule of AdministrationTwice dailyDrug 4 Generic/Working NameDasatinibDose70 mg per flat doseRoutep.o.Schedule of AdministrationTwice dailyDrug 5 Generic/Working NameEverolimusDose10 mg per flat doseRoutep.o.Schedule of AdministrationOnce dailyDrug 6 Generic/Working NameLapatinibDose1,250 mg per flat doseRoutep.o.Schedule of AdministrationOnce daily

Patient Characteristics {#onco12594-sec-0009}
=======================

Number of Patients, Male7Number of Patients, Female5StageIVAgeMedian (range): 62 (26--69)Number of Prior Systemic TherapiesMedian (range): 2 (1--3)Performance Status: ECOG0 --- 31 --- 92 --- 03 --- 0Unknown ---Cancer Types or Histologic SubtypesColorectal cancer 5Cholangiocarcinoma 3Gallbladder cancer 1Pancreatic cancer 1Germ cell cancer 1Synovial sarcoma 1

Primary Assessment Method {#onco12594-sec-0010}
=========================

TitleTotal patient populationNumber of Patients Screened13Number of Patients Enrolled12Number of Patients Evaluable for Toxicity12Number of Patients Evaluated for Efficacy8Evaluation MethodRECIST 1.0Response Assessment CR*n* = 0Response Assessment PR*n* = 0Response Assessment SD*n* = 1Response Assessment PD*n* = 7(Median) Duration Assessments PFS6 weeksOutcome NotesAccording to the study design, a stopping rule would apply if \<3 of 18 patients in stage I would have clinical benefit at 12 weeks of treatment. However, based on our findings after 11 treated patients that dasatinib was selected in 75% of patients, resulting in clinical benefit in \<10% of patients within 6 weeks, we concluded by statistical means that the chance for the trial to succeed to stage II according to prespecified criteria was \<1%. Therefore, the trial was prematurely halted. As a consequence, the secondary objective to determine the PFS~2~/PFS~1~ ratio of microarray‐selected PKI treatment became futile as well.

Adverse Events {#onco12594-sec-0011}
==============

imageJohn Wiley & Sons, Ltd.[^1][^2]

Assessment, Analysis, and Discussion {#onco12594-sec-0012}
====================================

CompletionStudy terminated before completionTerminated ReasonDid not fully accrueInvestigator\'s AssessmentLevel of activity did not meet planned endpoint

 {#onco12594-sec-0111}

This study represents the first attempt to predict the clinical activity of six approved protein kinase inhibitors (PKIs) in individual patients based on their in vitro activity in lysates from fresh‐frozen tumor biopsies, followed by selection of the most active agent for personalized treatment. Adult patients with progressive, measurable, and biopsy‐accessible disease of an unresectable and/or metastatic solid malignancy refractory to standard treatment, with Eastern Cooperative Oncology Group performance status of 0--2 were eligible. Tumor needle biopsies were taken with up to three passes under ultrasound‐ or computed tomography guidance. Biopsies with ≥50% tumor cells upon hematoxylin and eosin staining were considered representative. Kinase activity profiling was performed using a tyrosine kinase peptide substrate microarray (PamChip) consisting of 144 peptide substrates (PamGene, Hertogenbosch, The Netherlands), including phosphorylation sites for epidermal growth factor receptor, vascular endothelial growth factor receptor, and platelet‐derived growth factor receptor (Fig. [2](#onco12594-fig-0002){ref-type="fig"}) \[[9](#onco12594-bib-0009){ref-type="ref"}\]. Per patient, sunitinib, sorafenib, erlotinib, dasatinib, everolimus, and lapatinib were analyzed in vitro for their inhibition of kinase activity; the most potent PKI in this assay was then selected for treatment (Fig. [3](#onco12594-fig-0003){ref-type="fig"}). PKIs were prescribed according to standard dose and schedule. Treatment was continued until disease progression or unacceptable toxicity.

Thirteen patients, of whom five had metastatic colorectal cancer and four biliary tract cancer, were enrolled in the study and underwent tumor needle biopsy (Table [1](#onco12594-tbl-0001){ref-type="table"}). Kinase activity profiling was performed for 12 patients; dasatinib was selected for 9 patients, sunitinib for 2 patients, and erlotinib for 1 patient. Eleven patients subsequently initiated the selected treatment after a median of 17 days following tumor biopsy (Fig. [1](#onco12594-fig-0001){ref-type="fig"}). Algorithm scores for the selected PKIs are shown in Table [2](#onco12594-tbl-0002){ref-type="table"}. Eight of eleven patients who started treatment with the microarray‐selected PKI were evaluable for response. One patient reached the endpoint of clinical benefit at 12 weeks of treatment. This patient with gallbladder carcinoma had stable disease \>4 months on selected treatment with sunitinib. Of note, this drug has shown a 50% disease control rate in 54 patients with advanced, chemotherapy‐refractory biliary tract cancer but with a median duration of disease control of only 2.4 months \[[10](#onco12594-bib-0010){ref-type="ref"}\]. Although we showed that this selection strategy was technically and clinically feasible in this patient population, this resulted in a relative selection preference for dasatinib without subsequent evidence of clinical activity in the patients who went on to receive this drug. Therefore, after treatment of 11 patients, the study was halted for lack of drug selection and clinical activity and a calculated probability of less than 1% for the trial to succeed to stage II.

The (aberrant) biological activity of kinases in tumor cells is only one of the main determinants for response to treatment with PKIs. Other major contributing factors are the target specificity and affinity of the PKI for individual kinases that are biologically active and the bioavailability of the drug at the target site, in tumor cells \[[11](#onco12594-bib-0011){ref-type="ref"}\], \[[12](#onco12594-bib-0012){ref-type="ref"}\]. PKI bioavailability is multifactorially determined by chemical characteristics such as pH and lipophilicity that influence their intestinal uptake after oral ingestion, protein‐binding capacity, and ability to cross cell membranes. The latter will determine the circulating free concentration of a specific PKI and thereby its diffusion rate into the tumor microenvironment \[[13](#onco12594-bib-0013){ref-type="ref"}\]. The relative contribution of each of these determinants to response and their interplay are difficult to evaluate. We observed a striking disconnection between the potency of dasatinib in the assay and its lack of clinical activity in patients in this study. We hypothesize that the diffusion rate of dasatinib into the tumor microenvironment may be hampered by its high protein‐binding capacity causing its inactivity. Moreover, other factors contribute to the mismatch between conditions in vivo and the nonphysiological in vitro test setting. Besides an overrepresentation of Src substrates on chip, the anticipated clinical activity of dasatinib or other PKIs may be potentially overestimated by the reduced kinase specificity for the synthetic short peptides, as both the amino acid sequence context of the tyrosine phosphorylation site and the three‐dimensional structure of the substrate are known to contribute to this specificity \[[9](#onco12594-bib-0009){ref-type="ref"}\], \[[14](#onco12594-bib-0014){ref-type="ref"}\].

It is challenging to have information on kinase or pathway activity and target specificity, affinity, and bioavailability all at one\'s disposal. Information of (aberrant) kinase activity in tumor cells from patients is dependent on relative abundance, energy, and phosphorylation status of the cells, which is balanced by activity of kinases and phosphatases. Information on PKI potency and selectivity for target kinases can be obtained by high‐throughput screening platforms \[[15](#onco12594-bib-0015){ref-type="ref"}\]. Verification of adequate PKI accumulation in tumor tissue in patients during treatment is less straightforward. Tumor concentrations are not properly reflected by circulating concentrations in blood, as we and others have previously shown \[[13](#onco12594-bib-0013){ref-type="ref"}\], \[[16](#onco12594-bib-0016){ref-type="ref"}\], \[[17](#onco12594-bib-0017){ref-type="ref"}\]. Of interest, alternative approaches to predict tumor PKI concentrations may become available (e.g., by imaging using labelled drugs) \[[18](#onco12594-bib-0018){ref-type="ref"}\], \[[19](#onco12594-bib-0019){ref-type="ref"}\].

The benefits of the kinase activity‐profiling microarrays used in this study over other strategies include their high‐throughput usability and limited protein input requirements, enabling their implementation in clinical practice. However, label‐free mass spectrometry‐based tyrosine‐phosphoproteomics may be a complementary approach, as this allows for more unbiased and direct inference of signaling pathway or kinase activity. We have recently shown that this approach is feasible in small clinical samples, allowing the identification of patient‐specific but also PKI‐specific profiles \[[20](#onco12594-bib-0020){ref-type="ref"}\] (and Labots et al., unpublished data).

In conclusion, we here show that tumor needle biopsies from patients with refractory solid tumors provide sufficient tissue to reliably determine PKI inhibition profiles. However, this microarray‐based PKI selection strategy was insufficient in predicting subsequent clinical benefit upon treatment with the selected PKI. We anticipate that the PKI concentrations used in this in vitro assay should be re‐evaluated based on achieved PKI tumor concentrations in patients. In addition, PKI‐affinity/selectivity and mass spectrometry‐based (tyrosine) phosphorylation profiles may further guide development of predictive tools or biomarkers for PKI treatment benefit. Such an improved strategy is of utmost importance to realize the promise of personalized medicine for treatment selection in this high‐need patient population.

Figures and Tables {#onco12393-sec-6014}
==================

![Kinase activity measurement based on the PamChip (tyrosine kinase peptide substrate) microarray using a PamStation12 instrument. Per patient, control and inhibition samples were measured in triplicate using 5 µg lysate protein input per sample. Each run, based on three chips with four microarrays each, allows for simultaneous measurement of 12 samples. Shortly before application on the microarray, tumor lysate is mixed with kinase reaction buffer, containing the fluorescein‐labeled antiphosphotyrosine antibody pY20 as well as ATP, for phosphate transfer. In addition, for the inhibition samples, protein kinase inhibitors (PKIs) were spiked to the sample mix. Hereafter, incubation of the microarrays at 30°C is started for 60 cycles, during which the sample mix is transferred through the porous array once per minute. As a result of lysate kinase activity, (target) peptide substrates on chip will be phosphorylated at the tyrosine residue (Y), leading to phosphotyrosine formation, to which the fluorescein‐labeled antibody will bind. A 12‐bit charge‐coupled device camera monitors fluorescence intensities resulting from binding of the antiphosphotyrosine antibody over time. End levels of signal intensity, expressed in arbitrary units, after 60 minutes of incubation were determined for PKI‐spiked and control lysates. For each PKI, the percentage inhibition for all 144 peptide substrates on chip was calculated by dividing the mean end‐level signal intensity of the PKI‐spiked sample triplicates by the mean end‐level signal intensity of the control sample triplicates (end‐level intensity PKI/control). Peptide phosphorylation inhibition was considered to be significant if the *p* value calculated from a Student\'s *t* test was \<.05. Kinase enzymatic activity can be inferred from recorded intensity of peptide phosphorylation over time. XXXXXXYXXXXXX denotes peptide sequence context with tyrosine (Y) substrate flanked by six other amino‐acids.\
Abbreviations: ATP, adenosine triphosphate; P‐peptide, phosphorylated peptide.](onco12594-fig-0002){#onco12594-fig-0002}

![Per PKI, extrapolation of the ex‐vivo potency to their (potential) activity in patients was based on an algorithm considering the number of significantly inhibited peptides (columns) with, in the rows, their individual average percentage of inhibition (*left*). A PKI was considered to demonstrate no (significant) phosphorylation inhibition if the sum of the scores obtained from the algorithm was 0, low inhibition if the sum of the scores was 1, intermediate if 2 or 3, high if 4 or 5, and very high inhibition if this score was ≥6. In vitro, a PKI should at least result in intermediate phosphorylation inhibition to be considered significant and to thus be selected for therapy (*right*). In case ≥2 PKIs would display intermediate to very high inhibition, the agent with the highest cumulative score was selected for treatment of the patient. In case of equal scores, the least toxic drug was selected for treatment. Abbreviation: PKI, protein kinase inhibitor.](onco12594-fig-0003){#onco12594-fig-0003}

###### Patient characteristics

![](onco12594-tbl-0002){#nlm-graphic-15}

Patients for whom peptide microarray‐based kinase activity profiling was performed.

Patient not evaluable due to rapid deterioration.

Not applicable; patient turned ineligible after profiling.

Patient not evaluable, declined treatment after profiling.

Abbreviations: 6, PFS is 6 weeks; F, female; ID, identification; M, male; NA, not applicable; NE, not evaluable; PD, progressive disease; PFS, progression‐free survival; PKI, protein kinase inhibitor; SD, stable disease.

###### Summary algorithm scores

![](onco12594-tbl-0003){#nlm-graphic-17}

Table displays the selection algorithm scores for the PKIs dasatinib, sunitinib, and erlotinib (columns), reflecting their in vitro inhibitory potency, in the 12 patients (rows) for whom kinase activity profiling was performed. The median selection algorithm score for dasatinib in all 12 patients was 8 (range 6--10). In the nine patients for whom dasatinib was selected, this was 8.2, whereas the median score for sunitinib was 5.0 and 2.5 for erlotinib. For the two patients with sunitinib as most active drug in vitro, differences between the top three drugs were smaller. In these patients, the median algorithm score was 9.5 for sunitinib, 8.5 for dasatinib, and 8.0 for erlotinib. Data for lapatinib, everolimus, and sorafenib are not shown; the median algorithm selection score of these drugs in all 12 patients was 1 (range 0--6).

Abbreviations: NA, not applicable; PKI, protein kinase inhibitor.
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[^1]: Only grade ≥3 adverse events that were potentially related to the study treatment are shown. Treatment with dasatinib caused more significant toxicity compared with sunitinib and erlotinib (Common Terminology Criteria for Adverse Events grade ≥3 adverse events in 3/8 vs. 0/3 patients, respectively).

[^2]: Abbreviation: NC/NA, no change from baseline/no adverse event.
